Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report report published on Wednesday, December 27th. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a hold rating to a buy rating and set a $0.75 target price on the stock in a report on Monday, December 25th. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, December 12th. HC Wainwright reiterated a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, Roth Capital reiterated a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.74 on Wednesday. The company has a market cap of $59.22, a PE ratio of -1.57 and a beta of 41.30. Actinium Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $1.72.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/maxim-group-analysts-give-actinium-pharmaceuticals-atnm-a-3-00-price-target-updated-updated.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.